Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 1;26(6):e925–e935. doi: 10.1002/onco.13668

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

The best percentage from baseline in target lesions for the patients (n = 33) who had undergone at least one tumor assessment after treatment. Among these, three patients (two with PR, one with SD) terminated the treatment because of intolerable toxicity. (A): The response according to RECIST version 1.1: three patients achieved partial response; 23 had stable disease. (B): Five percent (2/40) of patients had obvious tumor necrosis and cavitation of lung metastasis. The response according to modified RECIST was PR.Abbreviations: PD, progression disease; PR, partial response; SD, stable disease.